Stock Ratings | Ascendiant Capital maintained its "buy" rating on IGC Pharma (IGC) and raised its price target to $5.50, implying a 1739.46% upside; Baird raised its price target for ABM Industries (ABM) to $48.
IGC Pharma, Inc. IGC | 0.00 | |
Lucid Diagnostics Inc. LUCD | 0.00 | |
Myomo, Inc. MYO | 0.00 | |
Incannex Healthcare IXHL | 0.00 | |
Cingulate, Inc. CING | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Ascendiant Capital: Maintaining a "buy" rating on IGC Pharma, Inc.(IGC.US) stock, while raising the price target from $5.25 to $5.5.
Ascendiant Capital: Maintains its "buy" rating on Lucid Diagnostics Inc.(LUCD.US) stock, raising its price target from $9 to $9.25.
Ascendiant Capital: Maintaining a "buy" rating on Myomo, Inc.(MYO.US) stock, while raising its price target from $9.50 to $10.00
Alliance Global Partners: Initial rating for Incannex Healthcare(IXHL.US) stock at "buy", with a target price of $18.
Ascendiant Capital: Maintains its "buy" rating on Cingulate, Inc.(CING.US) stock, while lowering its price target from $55 to $52.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| IGC Pharma, Inc.(IGC.US) | to lift | $5.5 | $0.299 | 1739.46% | Ascendiant Capital |
| Lucid Diagnostics Inc.(LUCD.US) | to lift | $9.25 | $0.9581 | 865.45% | Ascendiant Capital |
| Myomo, Inc.(MYO.US) | to lift | $10.0 | $1.28 | 681.25% | Ascendiant Capital |
| Allarity Therapeutics, Inc.(ALLR.US) | to lift | $10.25 | $1.58 | 548.73% | Ascendiant Capital |
| Shattuck Labs, Inc.(STTK.US) | to lift | $17.0 | $3.9 | 335.9% | Needham |
| Incannex Healthcare(IXHL.US) | Initial classification | $18.0 | $3.4 | 429.41% | Alliance Global Partners |
| Cingulate, Inc.(CING.US) | cut | $52.0 | $4.53 | 1047.9% | Ascendiant Capital |
| PAVmed, Inc.(PAVM.US) | cut | $56.0 | $5.18 | 981.08% | Ascendiant Capital |
| PLUS THERAPEUTICS INC(PSTV.US) | cut | $57.0 | $5.53 | 930.74% | Ascendiant Capital |
| ZenaTech, Inc.(ZENA.US) | cut | $5.0 | $1.39 | 259.71% | Maxim Group |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Baird: Maintaining a "neutral" rating on ABM Industries ( ABM Industries Incorporated(ABM.US) ), while raising the price target from $45 to $48.
B of A Securities: Maintaining a "buy" rating on Cisco Systems Cisco Systems, Inc.(CSCO.US) stock, while raising the price target from $135 to $150.
B of A Securities: Maintaining a "buy" rating on Fortinet Fortinet, Inc.(FTNT.US) ) stock, while raising the price target from $130 to $180.
First Coverage
Wells Fargo: Initial rating for BXDC ( Blackstone Digital Infrastructure Trust, Inc.(BXDC.US) ) at "overweight", with a target price of $26.
Morgan Stanley: Initial rating for GMRS Solutions ( GMR Solutions, Inc. Class A(GMRS.US) ) at "Market-in-Suit Weight", with a target price of $14.
Litchfield Hills: Initial rating for ZenaTech ( ZenaTech, Inc.(ZENA.US) ) at "Buy", with a target price of $4.
reduction
TD Cowen: Maintaining Adobe's ( Adobe Systems Incorporated(ADBE.US) ) rating at "Hold On", while lowering the target price from $310 to $285.
Guggenheim: Maintaining a "buy" rating on Five Below ( Five Below, Inc.(FIVE.US) ), while lowering the price target from $260 to $250.
TD Cowen: Maintaining a "buy" rating on Accenture ( Accenture Plc Class A(ACN.US) ), while lowering the price target from $282 to $258.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk warning:
Investing involves risk, and securities prices can rise or fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.